Hence, it is very likely that the combined strategy of osimertinib with a TRPM2 inhibitor will work well in these relapsed NSCLC with elevated TRPM2 because of the dependency of these tumors on TRPM2. Here, TRPM2 is linked to non-small cell lung carcinoma.